Sivik Global Healthcare Invests in CG Oncology

Got story updates? Submit your updates here. ›

Sivik Global Healthcare LLC, a healthcare-focused investment firm, has purchased a new stake of 35,000 shares in CG Oncology, Inc. (NASDAQ: CGON), a clinical-stage biopharmaceutical company developing novel antibody-based cancer treatments. The investment, valued at approximately $1.45 million, was disclosed in a recent 13F filing with the SEC.

Why it matters

CG Oncology's pipeline of experimental cancer immunotherapies has generated significant investor interest, as the company aims to leverage its platform to identify and optimize antibody candidates that target key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Sivik's investment signals confidence in CG Oncology's research and development efforts.

The details

According to the 13F filing, Sivik Global Healthcare purchased 35,000 shares of CG Oncology during the fourth quarter. The investment represents a new stake for the hedge fund in the clinical-stage biotech company. CG Oncology is headquartered in South San Francisco, California, and is focused on advancing its pipeline of antibody-based cancer immunotherapies through early-phase clinical trials.

• Sivik Global Healthcare purchased the 35,000 shares of CG Oncology during the fourth quarter of 2025.
• CG Oncology is a clinical-stage company, with its lead candidates currently in early-phase trials.

What’s next

CG Oncology is expected to provide updates on the progress of its early-phase clinical trials in the coming quarters, which could further drive investor interest in the company's novel cancer immunotherapy approaches.